Ongoing Clinical Trials in Prostate Cancer: The STAMPEDE Trial

patients with an allocation ratio of 2 patients into the control arm (arm A) to 1 patient into one of the 9 experimental arms, of which 6 arms are no longer recruiting after inclusion of more than 7,000 patients. Currently, patients are randomized into one of the remaining 3 arms (arm A, H and J), study completion date for final data collection for primary outcome measure is estimated for September 2017. Celecoxib (arm D) had shown antiproliferative effect against prostate cancer in vitro and has been evaluated as part of a phase II trial within the STAMPEDE trial. All other study arms are planned as a phase III trial. The primary outcome measure is overall survival (OS) with a targeted relative 25% OS improvement. Secondary study end points are failure-free survival, toxicity, quality of life, skeletal-related events, and cost effectiveness of the different treatments. Description